RxSight, Inc. (RXST)

From the record

RxSight, Inc.'s filings since 2017 show no warning events in the scan: no bankruptcy or receivership notice, no debt default notice, no exchange listing notice, no restatement warning, no auditor change, no material cyber incident and no late-report notice (its current reports).

From the record

RxSight, Inc.'s 6 filed years say what it did: revenue went from $15 million in fiscal 2020 to $134 million in fiscal 2025, up 55.7% a year; it rose in 4 of 5 years; the deepest fall was 4% from fiscal 2024 to fiscal 2025; net income was positive in 1 of 6 of those years (its annual reports).

From the record

Return on equity: in the fiscal year ended 2025-12-31, RxSight, Inc. lost about 14 cents for every dollar of shareholders' money, and gross profitability: its products earned about 33 cents per dollar of everything the company owns. Leverage: it owed about 12 cents per dollar of assets, and net share issuance: its share count grew 5.1% over the year (the filed statements).

From the record

RxSight, Inc.'s standing among 8 graded names in its industry family: revenue of $134 million in fiscal 2025 ranks in the bottom 19% by size; a net margin of -29% ranks in the bottom 31%; revenue growth of 40% a year over the last 3 filed years ranks in the top 19% (its annual reports).

From the record

RxSight, Inc.'s leadership, from its insiders' filings and its current reports: the chief executive on the record is Mottiwala, Aziz (President and CEO, as filed), filing under that title since 2026-07-24, 4 months (bottom 8% of its family); the 15 officers and directors filing in the last fifteen months have been on the record a median of 5.3 years (top 25%); 8 officer or director changes were reported on Form 8-K since 2023-11-13, against the 15 people in charge now (top 50%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.

From the record

RxSight, Inc.'s room to grow, from the newest filed statements (fiscal 2025): cash of $21 million against no long-term debt tagged leaves 6.6% of its assets as net cash, top 44% of its family; cash from operations less capital spending is -14.4% of revenue (bottom 31%); a gross margin of 76.6% (top 8%); research spending of 28.7% of revenue (top 8%) (its annual report).

From the record

RxSight, Inc.'s growth drivers, from the filed years to fiscal 2025: revenue grew 40% a year over the last three filed years against 55.7% over all 6, slowing (bottom 6% of its family); the newest year grew -3.9% (bottom 19%); research spending grew 14.1% a year (top 25%); capital spending grew 17% a year (top 19%) (its annual reports). RxSight, Inc. reported 3 product lines in fiscal 2025: Rxlal at $108 million (80%), LDD at $21 million (15%), Service Warranty Service Contracts and Accessories at $6 million (4%); 2 of 3 grew against the year before (its annual report).

From the record

RxSight, Inc.'s newest year against its own record: revenue of $134 million in fiscal 2025 came in 43.1% below the $236 million its prior three years' pace pointed to (bottom 6% of its family); net income of $39 million against a prior three-year average of $48 million (top 44%); a net margin of -29% against -70.1% before (top 19%) (its annual reports).